Drug Research
Non-Viral CRISPR May Potentially Boost Cell And Gene Therapy
A new variation of the CRISPR-Cas9 gene editing system, according to researchers from the Gladstone Institutes and University of California San Francisco (UCSF), enables the introduction of particularly long DNA sequences to specific locations in the genomes of cells...
Drug Research
Moderna Sues Pfizer, BioNTech Over mRNA COVID-19 Vaccines
According to complaints filed by Moderna, Pfizer and BioNTech's COVID-19 vaccine Comirnaty® violates patents the company filed between 2010 and 2016 that protect its core messenger RNA (mRNA) technology.
Both the Regional Court of Düsseldorf in Germany and the United...
Drug Research
Formulation Development Offshore Market To Be $60bn By 2030
A recent study predicts that the size of the global formulation development outsourcing market will increase from its value of $35.1 billion in 2022 to $61.4 billion by 2030, growing at a CAGR of 7.2%.
The researchers discovered that the...
Drug Research
NHS To Deploy Variant-Busting Booster Jab Ahead of Winter
The NHS has now laid out plans for the next stage of the COVID-19 vaccination effort, the biggest and most rapid vaccine drive in the history of the health service, in response to the updated guidelines outlined by the...
Drug Research
Priority Review of Lynparza If Paired With Abiraterone In US
Priority consideration has been given to AstraZeneca's supplemental new drug application for Lynparza (olaparib) when used in conjunction with abiraterone, prednisone, or prednisolone to treat elderly patients with advanced castration-resistant prostate cancer (mCRPC).
AstraZeneca and MSD, also known as Merck...
Drug Research
Trends of Genuv Cancer Drug Show Potential For Alzheimers
Mekinist (trametinib), which has been licenced by the FDA for the treatment of melanoma, was shown in a preclinical trial to have a neuroprotective impact on Alzheimer's disease, according to Genuv Inc. of South Korea, which has announced the...
Drug Research
Axsome Pitches Auvelity As A Depression Med Game-Changer
It is commonly known that there are insufficient therapy choices for major depressive disorder. Then the pandemic struck, increasing the number of patients with MDD diagnoses and the unmet demand.
In light of this, the time is right for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
